14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0060 $169.56 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Feb 07, 2019 $50.83 $50.84 $47.97 $49.48 675 650
Feb 06, 2019 $48.88 $51.37 $48.71 $50.92 820 391
Feb 05, 2019 $48.61 $50.42 $48.18 $48.87 619 201
Feb 04, 2019 $48.43 $49.56 $47.69 $48.80 546 035
Feb 01, 2019 $48.09 $48.49 $47.12 $48.44 352 746
Jan 31, 2019 $47.58 $48.20 $46.08 $47.91 641 188
Jan 30, 2019 $45.24 $47.50 $45.01 $47.48 694 228
Jan 29, 2019 $44.78 $45.70 $43.69 $44.90 346 117
Jan 28, 2019 $46.56 $46.56 $44.60 $44.68 453 087
Jan 25, 2019 $46.44 $47.00 $45.60 $46.86 431 187
Jan 24, 2019 $46.13 $46.38 $44.59 $46.11 460 231
Jan 23, 2019 $48.03 $48.47 $44.83 $45.97 670 457
Jan 22, 2019 $48.44 $48.76 $46.69 $47.82 655 918
Jan 18, 2019 $48.15 $48.93 $47.75 $48.87 580 638
Jan 17, 2019 $46.67 $48.30 $46.23 $47.91 440 504
Jan 16, 2019 $46.77 $48.13 $46.45 $46.75 549 525
Jan 15, 2019 $44.49 $46.83 $44.42 $46.76 737 086
Jan 14, 2019 $44.70 $45.68 $44.01 $44.25 620 201
Jan 11, 2019 $44.56 $46.64 $44.08 $45.21 703 188
Jan 10, 2019 $42.76 $44.87 $42.09 $44.64 789 057
Jan 09, 2019 $42.70 $43.49 $41.95 $42.90 798 745
Jan 08, 2019 $43.97 $43.97 $41.57 $42.62 1 116 551
Jan 07, 2019 $43.40 $44.69 $42.59 $43.49 984 986
Jan 04, 2019 $40.63 $42.64 $40.25 $42.20 1 133 042
Jan 03, 2019 $41.00 $41.54 $39.53 $39.99 706 422
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT